Connect with us

Cannabis News

Tilray’s Q2 2019 Report Reveals Stretched Losses Compared to Last Year Despite Better Performance

Published

on

Tilray (TLRY) to Acquire Calgary-based 420 Investments (Four20), Valued Up to $110 Million

Amidst the different efforts and improvements achieved by Canadian pharmaceutical and cannabis firm, Tilray, for the second quarter of this year, it was supposedly faced with a stretched-out debt.

As reported by MJ Headline News, the company incurred an unadjusted net loss of $35.1 million compared to last year’s second quarter loss of $12.8 million; amounting to a total of 174 percent. Some of the factors that contributed to said increase rests in a number of expenses including those related to operations focusing on expansion, interest expense and both Manitoba Harvest and Natura businesses.

Nonetheless, the firm has succeeded on a number of endeavors. For instance, compared to last year, the total kilogram sold has tripled from 1,514 kg to 5,588 kg. Similarly, the revenue increased by $371.1 percent, they were able to decrease net selling price from $6.38 to $4.61 due to reduced mix of higher priced extracts and gross margin increased from 23 to 27 percent.

Some of the areas that the company managed to secure deals in include capacity expansion (i.e. expanding international export cap. by signing deals to increase presence and making investments accordingly), international market developments (i.e. medical solutions launched in Ireland and Manitoba Harvest’s launch of broad-spectrum line accepted in the US), expanding brand portfolio, further developing the senior management team and involving themselves in a number of clinical research development.

Tilray’s President and CEO, Brendan Kennedy shared that the team is pleased with the results and overall performance of the company. He explicitly said:

“Our team has executed against our plan, with adult-use revenue nearly doubling in the second quarter compared to the first […] As we continue to grow, we remain focused on our long-term strategic objectives and deploying capital to maximize stockholder value.”

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.